1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Raptor Pharmaceuticals Acquires Quinsair

M&A Deal Summary

Raptor Pharmaceuticals Acquires Quinsair

On October 5, 2015, Raptor Pharmaceuticals acquired life science company Quinsair

Acquisition Highlights
  • This is Raptor Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Raptor Pharmaceuticals’ 1st transaction in the United States.

M&A Deal Summary
Date 2015-10-05
Target Quinsair
Sector Life Science
Buyer(s) Raptor Pharmaceuticals
Deal Type Add-on Acquisition

Target

Quinsair

United States
Quinsair is a proprietary inhaled formulation of levofloxacin, a fluoroquinolone antibiotic.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Raptor Pharmaceuticals

Novato, California, United States
Category Company
Founded 2005
Sector Life Science
Employees158
Revenue 110M USD (2016)
DESCRIPTION

Raptor Pharmaceutical Corp. is a bio pharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases. Raptor Pharmaceuticals Corp. was established in 2005 and is headquartered in Novato, California.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2015 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal